Most of any gains (or lack thereof) from here will be driven by just three factors.

Anthropic’s claim its AI agents discovered an unusual pattern in viral DNA similar to what’s seen in the gene-editing tool CRISPR Cas-9 has set off controversy.

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

Scientists have discovered a powerful gene-targeting system in viruses. Billions of years old, VIPR seems to predate CRISPR and may be even more powerful.

CRISPR Therapeutics AG remains a long-term Buy, anchored by Casgevy's success and management’s execution in ex vivo gene editing. Click for more on CRSP.

AI giant announces discovery amid global debate about how to safeguard against catastrophic risks.

A patient in Germany has been successfully treated with a drug based on CRISPR gene-editing technology for the first time ...

Anthropic's Claude autonomously found a CRISPR-like enzyme system called ART. Its function is unproven, and several ...

In recent decades, the global landscape of high-impact scientific and technological innovations has undergone a notable ...

A patient in Germany has been successfully treated with a drug based on the CRISPR gene-editing technology for the first time, the Charité medical school and hospital in Berlin announced on Thursday.

BCC Research examines how AI is improving gene transfer technologies through data-driven design, delivery optimization and ...